Yanjing Q. Tang

1678 Dongfang Road
Dongfang, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

Journal: JAMA oncology
Published: September 03, 2026

Long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy in pediatric patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

Long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy in pediatric patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal: Frontiers in medicine
Published: February 22, 2026

Efficacy of chimeric antigen receptor T-cell therapy in testicular relapse of pediatric acute lymphoblastic leukemia: a multicenter retrospective study.

Efficacy of chimeric antigen receptor T-cell therapy in testicular relapse of pediatric acute lymphoblastic leukemia: a multicenter retrospective study.

Journal: Frontiers in immunology
Published: December 12, 2025

CD19/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.

CD19/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation.

Journal: Haematologica
Published: November 04, 2025

Emapalumab in pediatric patients with high-grade cytokine release syndrome associated with CAR T-cell therapy.

Emapalumab in pediatric patients with high-grade cytokine release syndrome associated with CAR T-cell therapy.

Journal: Frontiers in immunology
Published: August 08, 2025

Bicistronic-CD19/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis.

Bicistronic-CD19/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis.

Journal: Kidney international reports
Published: August 01, 2025

Late-Onset Chimeric Antigen Receptor T-Cell Therapy-Associated Pneumonitis: A Case Report and Literature Review.

Late-Onset Chimeric Antigen Receptor T-Cell Therapy-Associated Pneumonitis: A Case Report and Literature Review.

Journal: Pediatric pulmonology
Published: July 11, 2025

Clinically associated genomic landscape of pediatric non-Down Syndrome acute megakaryoblastic leukemia in Chinese patients.

Clinically associated genomic landscape of pediatric non-Down Syndrome acute megakaryoblastic leukemia in Chinese patients.

Journal: Leukemia
Published: April 29, 2025

Durable remission achieved in pediatric patients with TCF3-HLF-positive relapsed/refractory B-cell acute lymphoblastic leukemia by dual CD19- and CD22-targeted chimeric antigen receptor T-cell therapy.

Durable remission achieved in pediatric patients with TCF3-HLF-positive relapsed/refractory B-cell acute lymphoblastic leukemia by dual CD19- and CD22-targeted chimeric antigen receptor T-cell therapy.

Journal: Haematologica
Published: December 02, 2024

Results from patient-derived xenograft models support co-administration of allopurinol and 6-mercaptopurine to reduce hepatotoxicity and improve event-free survival in pediatric acute lymphoblastic leukemia.

Results from patient-derived xenograft models support co-administration of allopurinol and 6-mercaptopurine to reduce hepatotoxicity and improve event-free survival in pediatric acute lymphoblastic leukemia.

Journal: Haematologica
Published: October 29, 2024

Impact of corticosteroids on the efficacy of CD19/22 CAR-T cell therapy in pediatric patients with B-ALL: a single-center study.

Impact of corticosteroids on the efficacy of CD19/22 CAR-T cell therapy in pediatric patients with B-ALL: a single-center study.

Journal: Frontiers in pediatrics
Published: August 23, 2024

Glycoprotein 350-targeted chimeric antigen receptor T-cell therapy for nonneoplastic chronic active Epstein-Barr virus infection: a case report.

Glycoprotein 350-targeted chimeric antigen receptor T-cell therapy for nonneoplastic chronic active Epstein-Barr virus infection: a case report.

Journal: Translational pediatrics
Published: July 30, 2024
Showing 1-12 of 35

Last Updated: 09/26/2026